Inivata announces collaboration with Maverick Therapeutics for use of RaDaR™ assay

RaDaR ctDNA liquid biopsy test to be used to monitor patient response in Phase 1/2 study of MVC-101 in multiple tumor types

Inivata, a leader in liquid biopsy, today announces a collaboration with Maverick Therapeutics (“Maverick”) for the use of Inivata’s RaDaR™ assay for the detection and monitoring of residual disease and recurrence. RaDaR will be used to monitor circulating tumor DNA (ctDNA) in patients enrolled in the Phase 1/2 study of MVC-101, Maverick’s lead program candidate.

MVC-101 is Maverick’s lead, conditionally active, T cell-engaging COBRA™ molecule designed to target Epidermal Growth Factor Receptor (EGFR), a protein expressed on both malignant and healthy tissues. As prodrugs, COBRAs are engineered to take advantage of the tumor microenvironment for T cell activation, triggering T cell-mediated tumor killing specifically at the site of the tumor while sparing damage to the patients’ healthy tissues. EGFR is expressed on a wide range of solid tumors, including but not limited to colorectal, head & neck, renal, pancreatic, cervical and non-small cell lung cancers. Maverick expects to initiate a Phase 1/2, open label, dose escalation study of MVC-101 in Q1 2021.

RaDaR is a personalized assay that tracks a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity, allowing both detection of residual disease following curative intent or definitive treatment, and early detection of relapse. As part of the MVC-101 clinical study RaDaR will be used to monitor response in the trial participants following treatment with MVC-101. These data will provide valuable early insights into the effectiveness of this novel bispecific platform and help to inform both the proof of concept and recommended Phase 2 dose.

Peter Collins, Chief Business Officer of Inivata, commented:

The collaboration with Maverick is in line with our strategy to secure biopharma partnerships that utilize RaDaR in clinical trial settings to enable earlier insight on the efficacy of drug candidates for solid tumors. By providing valuable insight into a particular patient’s disease state, the assay has the potential to make clinical trials more focused and efficient.

 

Jeremiah Degenhardt PhD, Vice President of Translational Oncology & Bioinformatics at Maverick Therapeutics, commented: “ctDNA has shown promise as a predictive marker of early response for immunotherapies in solid tumor indications. The patient-specific design of the RaDaR assay enables the detection of residual disease with exceptional sensitivity in multiple tumor types and it is therefore a highly complementary technology to advance our Phase 1/2 study. The use of RaDaR will enable our team to more accurately measure treatment success throughout the trial for our novel COBRA platform.”

Read the full press release here